New drug SHR6508 aims to tame hormone imbalance in dialysis patients
NCT ID NCT06434961
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new drug called SHR6508 in 498 adults on hemodialysis who have secondary hyperparathyroidism, a condition where the parathyroid glands make too much hormone. The drug is given during dialysis and was compared to an existing oral medication, cinacalcet. The goal was to see if SHR6508 can safely lower parathyroid hormone levels by at least 30%.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SHR6508 (a drug given intravenously during dialysis to lower parathyroid hormone levels)
What this could lead to
If successful, SHR6508 could offer a new treatment option for controlling secondary hyperparathyroidism in kidney dialysis patients, potentially with fewer side effects than current therapies.
What could go wrong
This is a completed Phase 3 trial, but results are not yet published. The drug may not prove superior to existing treatments like cinacalcet, and side effects such as nausea and vomiting are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SECONDARY HYPERPARATHYROIDISM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, 510000, China